According to Roger White, the bladder cancer's revenue opportunity in the US alone is $3billion and an additional $9billion the rest of the world. 

Conservatively, 1 out of 4 patients would prefer the Theralase treatment so this could mean an annual revenue before expenses of $3billions for the company alone. 

P/E ratio of 15x should put us at $60billion market cap easily and let's just say we did end up with 200million shares from PP. This should put us at $225/share in 2-3years and I'll take that with a big smile. AND if 2 out of 4 patients prefer Theralase treatment?? well $450/share is not that far. Note that we are only at 135mil shares (fully dilluted) so my estimates are really conservative.

Now to make it even better... Note that Theralase has another product for brain cancer which is also promising and  I'm guessing it will start the Phase 1 after the commercialization of the NMIB Theralase cure. This brain cancer cure by Therelase can prolong the life of a patient by 5 years - 8 years compared to the current cure that only prolongs a patient's life by a year or so.. NOW that is a major changer too. 


Lol don't worry I didn't make this up.. .here's the link of the interview.

https://www.youtube.com/watch?v=0YduNy4_9A8